166 related articles for article (PubMed ID: 17579081)
1. Broad TCR usage in functional HIV-1-specific CD8+ T cell expansions driven by vaccination during highly active antiretroviral therapy.
Yang H; Dong T; Turnbull E; Ranasinghe S; Ondondo B; Goonetilleke N; Winstone N; di Gleria K; Bowness P; Conlon C; Borrow P; Hanke T; McMichael A; Dorrell L
J Immunol; 2007 Jul; 179(1):597-606. PubMed ID: 17579081
[TBL] [Abstract][Full Text] [Related]
2. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
3. Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine.
Dorrell L; Yang H; Ondondo B; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Bowness P; Goonetilleke N; Rostron T; Rowland-Jones S; Hanke T; McMichael A
J Virol; 2006 May; 80(10):4705-16. PubMed ID: 16641264
[TBL] [Abstract][Full Text] [Related]
4. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
Ondondo BO; Yang H; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Rowland-Jones SL; Hanke T; McMichael AJ; Dorrell L
Eur J Immunol; 2006 Oct; 36(10):2585-94. PubMed ID: 17013989
[TBL] [Abstract][Full Text] [Related]
5. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1-infected patients after immunizations with an HIV type 1 lipopeptide vaccine.
Gahery H; Daniel N; Charmeteau B; Ourth L; Jackson A; Andrieu M; Choppin J; Salmon D; Pialoux G; Guillet JG
AIDS Res Hum Retroviruses; 2006 Jul; 22(7):684-94. PubMed ID: 16831093
[TBL] [Abstract][Full Text] [Related]
6. Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.
Chen Z; Huang Y; Zhao X; Ba L; Zhang W; Ho DD
J Acquir Immune Defic Syndr; 2008 Apr; 47(4):412-21. PubMed ID: 18209682
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
Dorrell L; Williams P; Suttill A; Brown D; Roberts J; Conlon C; Hanke T; McMichael A
Vaccine; 2007 Apr; 25(17):3277-83. PubMed ID: 17257714
[TBL] [Abstract][Full Text] [Related]
8. MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays.
Kutscher S; Allgayer S; Dembek CJ; Bogner JR; Protzer U; Goebel FD; Erfle V; Cosma A
Gene Ther; 2010 Nov; 17(11):1372-83. PubMed ID: 20535218
[TBL] [Abstract][Full Text] [Related]
9. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens.
Friedman RS; Frankel FR; Xu Z; Lieberman J
J Virol; 2000 Nov; 74(21):9987-93. PubMed ID: 11024127
[TBL] [Abstract][Full Text] [Related]
10. Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells.
Payne RP; Kløverpris H; Sacha JB; Brumme Z; Brumme C; Buus S; Sims S; Hickling S; Riddell L; Chen F; Luzzi G; Edwards A; Phillips R; Prado JG; Goulder PJ
J Virol; 2010 Oct; 84(20):10543-57. PubMed ID: 20686036
[TBL] [Abstract][Full Text] [Related]
11. Cross-clade protection induced by human immunodeficiency virus-1 DNA immunogens expressing consensus sequences of multiple genes and epitopes from subtypes A, B, C, and FGH.
Malm M; Rollman E; Ustav M; Hinkula J; Krohn K; Wahren B; Blazevic V
Viral Immunol; 2005; 18(4):678-88. PubMed ID: 16359234
[TBL] [Abstract][Full Text] [Related]
12. Greater CD8+ TCR heterogeneity and functional flexibility in HIV-2 compared to HIV-1 infection.
Lopes AR; Jaye A; Dorrell L; Sabally S; Alabi A; Jones NA; Flower DR; De Groot A; Newton P; Lascar RM; Williams I; Whittle H; Bertoletti A; Borrow P; Maini MK
J Immunol; 2003 Jul; 171(1):307-16. PubMed ID: 12817012
[TBL] [Abstract][Full Text] [Related]
13. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.
Gómez CE; Nájera JL; Jiménez V; Bieler K; Wild J; Kostic L; Heidari S; Chen M; Frachette MJ; Pantaleo G; Wolf H; Liljeström P; Wagner R; Esteban M
Vaccine; 2007 Mar; 25(11):1969-92. PubMed ID: 17224219
[TBL] [Abstract][Full Text] [Related]
14. Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection.
Wilson SE; Pedersen SL; Kunich JC; Wilkins VL; Mann DL; Mazzara GP; Tartaglia J; Celum CL; Sheppard HW
AIDS Res Hum Retroviruses; 1998 Jul; 14(11):925-37. PubMed ID: 9686639
[TBL] [Abstract][Full Text] [Related]
15. Vaccination with a fusion protein that introduces HIV-1 gag antigen into a multitrimer CD40L construct results in enhanced CD8+ T cell responses and protection from viral challenge by vaccinia-gag.
Gupta S; Termini JM; Raffa FN; Williams CA; Kornbluth RS; Stone GW
J Virol; 2014 Feb; 88(3):1492-501. PubMed ID: 24227853
[TBL] [Abstract][Full Text] [Related]
16. mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients.
Van Gulck E; Vlieghe E; Vekemans M; Van Tendeloo VF; Van De Velde A; Smits E; Anguille S; Cools N; Goossens H; Mertens L; De Haes W; Wong J; Florence E; Vanham G; Berneman ZN
AIDS; 2012 Feb; 26(4):F1-12. PubMed ID: 22156965
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes.
Woodberry T; Gardner J; Mateo L; Eisen D; Medveczky J; Ramshaw IA; Thomson SA; Ffrench RA; Elliott SL; Firat H; Lemonnier FA; Suhrbier A
J Virol; 1999 Jul; 73(7):5320-5. PubMed ID: 10364278
[TBL] [Abstract][Full Text] [Related]
18. Priming with a recombinant pantothenate auxotroph of Mycobacterium bovis BCG and boosting with MVA elicits HIV-1 Gag specific CD8+ T cells.
Chapman R; Shephard E; Stutz H; Douglass N; Sambandamurthy V; Garcia I; Ryffel B; Jacobs W; Williamson AL
PLoS One; 2012; 7(3):e32769. PubMed ID: 22479338
[TBL] [Abstract][Full Text] [Related]
19. Repertoire and immunofocusing of CD8 T cell responses generated by HIV-1 gag-pol and expression library immunization vaccines.
Singh RA; Barry MA
J Immunol; 2004 Oct; 173(7):4387-93. PubMed ID: 15383568
[TBL] [Abstract][Full Text] [Related]
20. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
